Multicell Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2013
July 24, 2013 at 12:20 pm IST
Share
MultiCell Technologies, Inc. reported earnings results for the second quarter and six months ended May 31, 2013. For the quarter, the company reported net loss attributable to the company of $241,517, or $0.00014 loss per share, compared to a net loss attributable to the company of $378,759, or $0.00040 loss per share, for the same quarter ended May 31, 2012. Revenues were $12,330, compared to $12,330 million for the same quarter of ended May 31, 2012.
For the six months, net loss attributable to the company was $600,482 million, or $0.00039 loss per share, compared to a net loss attributable to the company of $649,329 million, or $0.00072 loss per share, for the same period ended May 31, 2012. Revenues were $24,659 million, compared to $24,659 million for the same period ended May 31, 2012.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.